United States Prescription Dermatological Drugs (PDD) Market Growth Expansion Till 2032 | Most Leading Companies - Astellas Pharma, Inc, Biofrontera AG, Bristol-Myers Squibb, Dermira, Inc., Glaxosmithkline Plc

DataM Intelligence has published a new research report on "Prescription Dermatological Drugs Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Atopic dermatitis (AD) is a common chronic inflammatory skin condition, affecting 15-20% of children and 1-3% of adults globally. According to the National Institutes of Health (NIH), acne ranks as the eighth most prevalent disease worldwide, impacting 9.4% of the global population.

Sirnaomics secured a $105 million Series D funding round to advance R&D of its RNAi therapeutics targeting skin cancer, fibrosis, metabolic diseases, and viral infections. Vyome Therapeutics Inc. also raised $22 million to progress its lead molecule, VB 1953, into Phase II clinical trials for moderate to severe acne treatment and support operations. Additionally, institutions and organizations have been increasingly investing in dermatology-related research, with the National Institutes of Health (NIH) allocating substantial funding to numerous projects across multiple institutions, reflecting growing support for innovation in the dermatology field.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/prescription-dermatological-drugs-market

Epidemiology

According to the American Cancer Society, melanoma remains a significant health concern in the United States, with tens of thousands of new cases reported annually and thousands of related deaths. The National Alopecia Areata Foundation estimates that about 6.8 million people in the U.S. either have or will develop alopecia areata, while the American Hair Loss Association notes that approximately 95% of male hair loss cases are attributed to androgenetic alopecia.

The prevalence of atopic dermatitis is around 7-8% across Central and Eastern Europe, with France reporting similar rates among adults. Factors such as urban living, higher socioeconomic status, and family history contribute to an increased risk of developing the condition. In the U.S., acne vulgaris affects up to 80% of individuals at some point in their lives, and about 20% of severe cases lead to lasting physical and psychological scarring.

Key Players:

Johnson & Johnson Inc., Merck & Co., Inc., Bayer AG, Pfizer, F. Hoffmann-La Roche, Allergan, Abbvie, Inc, Astellas Pharma, Inc, Biofrontera AG, Bristol-Myers Squibb, Dermira, Inc., Glaxosmithkline Plc, and Mylan N.V.

Growth Forecast Projected:

The Global Prescription Dermatological Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Prescription Dermatological Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=prescription-dermatological-drugs-market

Key Segments:

By Product Type: ( Acne & Rosacea Drugs, Anti-Aging Drugs, Dermatitis & Seborrhea Drugs, Hair Loss & Hair Removal Drugs, Psoriasis Drugs, Skin Cancer Drugs, Others)

By Route of Administration: (Topical, Oral, Parenteral, Others)

By Distribution Channel: (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Acquisition:

Eli Lilly and Company acquired Dermira, Inc., expanding its immunology pipeline with lebrikizumab, a monoclonal antibody targeting IL-13 for moderate-to-severe atopic dermatitis. Johnson & Johnson acquired Momenta Pharmaceuticals for about $6.5 billion, strengthening its position in immune-mediated diseases. LEO Pharma also acquired Bayer's global prescription dermatology business, gaining global product rights and a production facility in Italy to expand its dermatology portfolio.

Partnership:

Repurpose.AI partnered with LEO Pharma to leverage its ActivPred AI Drug Discovery Platform for identifying and validating new treatments for inflammatory and dermatological conditions.

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Prescription Dermatological Drugs producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Prescription Dermatological Drugs revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/prescription-dermatological-drugs-market?kb

FAQ's

Q1: How fast is the Prescription Dermatological Drugs Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 6.20% from 2025 to 2032

Q2: Which regions are dominating the Prescription Dermatological Drugs Market and which are fastest-growing?

A: North America dominating the Prescription Dermatological Drugs market.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/prescription-dermatological-drugs-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.